Earnings ·
Arvinas reports Q3 loss of $53.9M, cash position falls to $558.9M
ARVNArvinas, Inc.
Arvinas reported a net loss of $53.9 million for the third quarter ended September 30, 2026, compared to a loss of $35.1 million in the prior-year period. Revenue dropped to $0.5 million from $41.9 million as Pfizer collaboration payments ceased following the Rigel license agreement. Research and development expenses decreased to $46.9 million from $64.7 million due to lower external costs. The company's cash, cash equivalents, restricted cash, and marketable securities position fell to $558.9 million from $685.4 million at year-end 2025. Arvinas reaffirmed its commitment to share clinical data for ARV-393, ARV-027, and ARV-6723 in late 2026 and 2027, while initiating dosing in the Phase 1/2 trial of its immuno-oncology candidate ARV-6723. Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapies.